Asia Fresh News

Asia Fresh Stories

Archive for July 19th, 2016

Merck Relaunches Customer Collaboration Centers with New Concept and M Lab(TM) Name

leave a comment »

— State-of-the-art laboratories for full end-to-end process development support and training
— Enables explorations of new technologies and solutions to address development and manufacturing challenges
— Dynamic settings in major pharmaceutical and biotechnology hubs promote customer collaboration from pre-clinical through full-scale production
DARMSTADT, Germany /PRNewswire/ — Merck, a leading science and technology company, is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges and helping accelerate development of new therapies.

Photo –
Photo –

Formerly known as biomanufacturing science training centers, the new state-of-the art M Lab™ Collaboration Centers provide a simulated manufacturing environment for experiments, troubleshooting and problem solving, in a non-GMP setting, that fosters education and full end-to-end process development support. Customers participate in product demonstrations, hands-on training and proof-of-concept work, as well as apply best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer.

“These centers have been an important resource for our customers and the biopharma industry for more than two decades,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “Now reimagined and reengineered as M Lab™ Collaboration Centers, we have taken our industry-leading concept to the next level. We are creating unique and inspiring settings where customers can explore new ways to increase productivity and improve processes in close collaboration with our team of experts.”

Merck unveiled its first remodeled center in Tokyo, Japan on June 29, 2016. The network, established in 1995, will also include locations in Brazil, China, France, India, Singapore, South Korea and the United States with formal relaunch of centers around the world taking place throughout the remainder of 2016 and 2017.

Each M Lab™ Collaboration Center will welcome customers and collaboration partners from government, academia, regulatory bodies and industry associations, offering application best practices and knowledge sharing tailored to address the specific needs of the local pharmaceutical manufacturers. Customers will have access to sizing and simulation tools and methodologies as well as analytical and modeling support and customer education programs.

Click here to learn more about the M Lab™ Collaboration Centers and view videos of Merck’s facilities.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life — from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of EUR12.85 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Source: Merck
Related Links:

Written by asiafreshnews

July 19, 2016 at 5:41 pm

Posted in Uncategorized

Xura’s Signaling Fraud Management Solution Goes Broader, Deeper and Faster into the Network

leave a comment »

WAKEFIELD, Massachusetts /PRNewswire/ —

Enhanced and integrated SS7 and Diameter signaling security solution protects operators’ networks, revenues and subscribers from vulnerabilities and attacks

Xura, Inc. (NASDAQ: MESG), a leading provider of digital communications services, today announces the latest enhancements to its world-class signaling security solutions, providing operators with the broadest, deepest and fastest response to controlling vulnerabilities across any signaling network.

Challenges in SS7 signaling security are well publicized, highlighting the potential risk posed to operators’ networks, their revenues and their subscribers. Similar vulnerabilities exist in Diameter signaling networks, which also has additional protocol-specific flaws that must be addressed. Despite rapid evolution of LTE networks, legacy SS7 signaling will continue to co-exist with new protocols for many years to come. Vulnerabilities in each protocol need securing in their own right. However, the co-existence of SS7 and Diameter signaling opens up the threat of multi-vector attack mechanisms that span both protocols and therefore signaling protection also requires an integrated approach.

The combined functionality of SS7, Diameter and SIP protection integrated within Xura’s Signaling Fraud Management solution provides the means to detect and prevent attacks carried by each protocol and, moreover, it protects networks from the threat of multi-vector attacks.

Speed of reaction to new threats is critical for any security solution, in order to adequately protect against fast developing threats and enable an immediate remedy to minimize the operators’ exposure to risk. Solutions that depend on the vendor to turn threat intelligence into active protection introduces delays that prolong the exposure to risk, as well as adding cost to the solution. Xura’s approach provides powerful, integrated analytics that puts threat intelligence into the hands of the operator in near real-time. More importantly, the solution also empowers the operator to rapidly build additional defenses, with real-time tooling to help validate their efficacy.

Ilia Abramov, Product Director of Security Solutions at Xura, said: “We continue to invest in extending the lead our solutions have in the market. Other vendors are only now announcing forthcoming capabilities that Xura’s products have been providing to our customers for quite some time. While our products give unrivalled breadth and depth to signaling analytics, we are even more focused on providing the capabilities that enable the fastest path from threat intelligence to protective action, giving greater control all from one solution.”

Over the past decade, Xura has provided early stage SS7 security solutions to a large number of its 350+ customers around the world. The company’s Diameter Routing Agent (DRA), Diameter Intelligent Signaling Controller, includes Diameter signaling security capabilities when it first launched more than two years ago. The capabilities of Xura’s signaling security products have since been extended to provide protection beyond the industry’s current base-line recommendations, and further significant investment in R&D is underway.

Xura currently works with operators across North America, Latin America, Europe, Russia and Asia-Pacific to ensure that they not only have visibility of the threats and vulnerabilities exposed, but have the solutions in place to protect their networks, revenue and the subscribers they serve.

To find out more about Xura’s network security products including Spam Shield and Signaling Fraud Management, please visit or email:

About Xura, Inc.

Xura, Inc (NASDAQ: MESG) offers a portfolio of digital services solutions that enable global communications across a variety of mobile devices and platforms. We help communication service providers (CSPs) and enterprises navigate and monetise the digital ecosystem to create innovative, new experiences through our cloud-based offerings. Our solutions touch more than three billion people through 350+ service providers and enterprises in 140+ countries. You can find us at

Forward-Looking Statements

This press release includes “forward-looking statements.” Forward-looking statements include statements of plans and objectives for future operations, statements of future economic performance, and statements of assumptions relating thereto. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “expects,” “plans,” “anticipates,” “estimates,” “believes,” “potential,” “projects,” “forecasts,” “intends,” or the negative thereof or other comparable terminology. By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results, performance and the timing of events to differ materially from those anticipated, expressed or implied by the forward-looking statements in this press release. These risks and uncertainties discussed above, as well as others, are discussed in greater detail in our filings with the SEC. The documents and reports we file with the SEC are available through us, or our website,, or through the SEC’s Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) at

Source: Xura, Inc.
Related stocks: NASDAQ-NMS:MESG
Related Links:

Written by asiafreshnews

July 19, 2016 at 5:37 pm

Posted in Uncategorized

Russian E-commerce Leader Ulmart to Host Russia House at WEF ’17

leave a comment »

ST. PETERSBURG, Russia /PRNewswire/ —

Coming off successful participation at the St. Petersburg International Economic Forum (SPIEF) in Russia and World Economic Forum’s (WEF) Annual Meeting of New Champions in Tianjin, China, Ulmart was tapped by the Russian government to create a unique business program for WEF’s annual meeting in Davos, Switzerland in January, 2017 at what is officially now called “Russia House 2017 (RH17)”.

(Logo: )

In collaboration with Roscongress–official organizer for all Russian economic forums/conferences–Ulmart will seek to build on its success from WEF 2016 when it hosted the “Ulmart House of Innovation (UHI).” The UHI was visited by over 1500 people in three days from 23 countries.

“As leaders in the digital transformation underway in Russia, and obviously active participants in the 4th industrial revolution (4th IR), our chairman of the board, Dmitry Kostygin, at the end of our successful WEF this year challenged us to take a more proactive role in shaping not just Ulmart’s image but Russia’s message also at WEF ’17,” explained Brian Kean, Chief International Officer for Ulmart.

Like last year, Russia House will be located at the Davos-famous Kaffee Klatsch located at Promenade 72; but, whereas last year focus was on Ulmart and digital companies, this year the house will be opened to all Russian companies, media and even some government officials.

In addition to RH activities, to include up to six business discussions on Russia’s role in the 4th IR, the current investment climate and growth expectations for the Russian economy in 2017, there will be a slew of cultural events hosted as well in venues throughout Davos.

“We plan to create a Russian presence at WEF 2017…wherever one turns, they will see aspects of Russia that drastically differ from the misperceptions we have been forced to deal with as we tell our story to the world,” added Kostygin. “Davos ’17 will be remembered as the year Russian business of the ‘new economy’ stormed back onto the world stage.”

WEF’s annual meeting takes a bird’s eye view of the world and contemplates current problems and issues.

“The annual meeting inspires CEO’s and leaders from all over the world. At the RH, we will take this inspiration to the next level and target it at our own commercial and economic realities and hopefully learn so as to grow the Russian economy,” mused Mr. Kean.

Source: Ulmart

Written by asiafreshnews

July 19, 2016 at 5:29 pm

Posted in Uncategorized

ARIA Study Shows Superior Efficacy of Triumeq(R) for Treatment-naive Women Living with HIV

leave a comment »

LONDON, England and DURBAN, South Africa /PRNewswire/ — ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 495 treatment-naive women living with HIV.[1] Results show statistically superior viral suppression (HIV-1 RNA 50c/mL) in the dolutegravir/abacavir/lamivudine arm (6%) compared to the other group (14%) at week 48.[1] Of the women that met protocol-defined virologic withdrawal criteria, none on the dolutegravir/abacavir/lamivudine arm had treatment-emergent resistance mutations to the components of dolutegravir/abacavir/lamivudine, compared with one in the comparator group.[1]

About HIV

HIV stands for the Human Immunodeficiency Virus. Unlike some other viruses, the human body cannot get rid of HIV, so once someone has HIV they have it for life. There is no cure for HIV, but effective treatment can control the virus so that people with HIV can enjoy healthy and productive lives.[2]

About HIV in women

Globally, HIV/AIDS is the leading cause of death for women of reproductive age (15-44 years old)[3] and infection rates in young women (aged 15-24) are twice as high as those seen in young men.[4] Despite the scale of the challenge, women are routinely under-represented in HIV clinical trials.[5] This may be in part due to lack of child-care services, exclusions from study protocols due to the potential for pregnancy and lack of support in the home.[5] As a result there are gaps in our knowledge about issues regarding antiretroviral treatments that are particular to women.[5]

ARIA study design

ARIA is a phase IIIb randomised, open-label, international, multi-centre study designed to demonstrate the non-inferior antiviral activity of fixed-dose dolutegravir/abacavir/lamivudine (Triumeq) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve adult women over 48 weeks.[6] While ARIA is a non-inferiority study, there was a pre-specified analysis for superiority. ARIA also evaluated the safety and tolerability of dolutegravir/abacavir/lamivudine compared to ATV/r plus TDF/FTC arm.[6] 495 treatment-naive adult women were enrolled in the study.[6]

About Triumeq®

Triumeq is a once-daily dolutegravir-based regimen, containing the un-boosted integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.

Two essential steps in the HIV life cycle are replication – when the virus turns its RNA copy into DNA – and integration – the moment when viral DNA becomes part of the host cell’s DNA. These processes require two enzymes called reverse transcriptase and integrase. NRTIs and INSTIs interfere with the action of the two enzymes to prevent the virus from replicating. This decrease in replication will lead to less virus being available to cause subsequent infection of uninfected cells.

The latest data for Triumeq, including the ARIA data presented at IAC 2016,[1] build on existing clinical trial data demonstrating that dolutegravir-based regimens are efficacious and generally well-tolerated in a broad range of people living with HIV (PLHIV), including treatment-naïve, treatment-experienced and those who have developed resistance to multiple HIV drugs.[7],[8],[9],[10],[11]

Triumeq is a registered trademark of the ViiV Healthcare group of companies.

Important Safety Information (ISI) for Triumeq® (abacavir, dolutegravir, and lamivudine) tablets[12]

Note: this is taken from the US label and local variations apply. Please refer to applicable local labelling.

FDA Indications and Usage: Triumeq is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Limitations of Use:

Triumeq alone is not recommended in patients with:

Current or past history of resistance to any components of Triumeq
Resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in Triumeq is insufficient in these subpopulations. See full prescribing information for dolutegravir

Hypersensitivity Reactions:

Serious and sometimes fatal hypersensitivity reactions have occurred with abacavir-containing products
Hypersensitivity to abacavir is a multi-organ clinical syndrome
Patients who carry the HLA-B*5701 allele are at a higher risk of experiencing a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele
Triumeq is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy or reinitiation of therapy with Triumeq, unless patients have a previously documented HLA-B*5701 allele assessment
Discontinue Triumeq as soon as hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue Triumeq if hypersensitivity cannot be ruled out, even when other diagnoses are possible
Following a hypersensitivity reaction to Triumeq, NEVER restart Triumeq or any other abacavir-containing product
Lactic Acidosis and Severe Hepatomegaly with Steatosis:

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues
Exacerbations of Hepatitis B:

Severe acute exacerbations of HBV have been reported in patients who are co-infected with HBV and HIV-1 and have discontinued lamivudine, a component of Triumeq. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment

Triumeq is contraindicated in patients:

who have the HLA-B*5701 allele
with prior hypersensitivity reaction to abacavir, dolutegravir, or lamivudine
receiving dofetilide (antiarrhythmic)
with moderate or severe hepatic impairment

Hypersensitivity Reactions to Dolutegravir:

Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury. The events were reported in <1% of subjects receiving TIVICAY® in Phase 3 clinical trials
Clinically, it is not possible to determine whether a hypersensitivity reaction with Triumeq would be caused by abacavir or dolutegravir. Discontinue Triumeq and other suspect agents immediately if signs or symptoms of hypersensitivity reaction develop
Effects on Serum Liver Biochemistries in Patients with Hepatitis B or C Co-infection:

Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of Triumeq. In some cases the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation, particularly in the setting where anti-hepatitis therapy was withdrawn
Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with Triumeq are recommended in patients with underlying hepatic disease such as hepatitis B or C
Use With Interferon- and Ribavirin-based Regimens: Hepatic decompensation, some fatal, has occurred in HIV-1/hepatitis C virus (HCV) co-infected patients receiving combination antiretroviral therapy and interferon alfa with or without ribavirin. Patients receiving interferon alfa with or without ribavirin and Triumeq should be closely monitored.

Immune Reconstitution Syndrome: including the occurrence of autoimmune disorders with variable time to onset, has been reported.

Fat Redistribution or accumulation has been observed in patients receiving antiretroviral therapy.

Myocardial Infarction (MI):

An observational study showed an increase in MI with abacavir; a sponsor-conducted, pooled analysis did not show increased risk. In totality, the available data are inconclusive
The underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, smoking)
Use With Certain Antiretroviral Products: Triumeq should not be administered concomitantly with other products containing abacavir or lamivudine.

ADVERSE REACTIONS: The most commonly reported (≥2%) adverse reactions of at least moderate intensity in treatment-naïve adults receiving Triumeq were insomnia (3%), headache (2%), and fatigue (2%).


Co-administration of Triumeq with certain inducers of UGT1A and/or CYP3A may reduce plasma concentrations of dolutegravir. Consult the full Prescribing Information for Triumeq for more information
Administer Triumeq 2 hours before or 6 hours after taking polyvalent cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, Triumeq and supplements containing calcium or iron can be taken with food
Pregnancy Category C: Triumeq should be used during pregnancy only if the potential benefit justifies the potential risk. An Antiretroviral Pregnancy Registry has been established
Nursing Mothers: Breastfeeding is not recommended due to the potential for HIV transmission and the potential for adverse reactions in nursing infants
Patients with Impaired Renal Function: Triumeq is not recommended in patients with creatinine clearance <50 mL/min
Patients with Impaired Hepatic Function: If a dose reduction of abacavir, a component of Triumeq, is required for patients with mild hepatic impairment, then the individual components should be used
Full US Prescribing Information for Triumeq is available at:

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi (TYO: 4507) joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit

1. C. Orell et al. Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA Study). Presented at the International AIDS Conference (IAC), 18-22 July 2016, Durban, South Africa. Abstract #10215.

2. World Health Organization (WHO). 2016. HIV/AIDS media fact sheet. Available at: Last accessed July 2016.

3. UNAIDS, 2016-2021 Strategy On the Fast-Track to end AIDS. Available at: Last accessed July 2016.

4. UNAIDS Factsheet – Adolescents, young people and HIV. Available at: Last accessed July 2016.

5. Curno, J. Mirjam et al. A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies. Journal of Acquired Immune Deficiency Syndromes (JAIDS). 2016 Feb 1;71(2):181-8.

6. (NCT01910402). Available at: Last accessed June 2016.

7. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril J-G, Domingo P, Brennan C, Almond S, Min S, for the SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-935.

8. Walmsley S, Baumgarten A, Berenguer J, et al. Brief Report: Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in Antiretroviral therapy-naïve patients: Week 96 and Week 144 Results from the SINGLE randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes (JAIDS). 2015;70(5):515-519.

9. Molina J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2:e127-136.

10. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S, for the extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700-708.

11. Castagna S, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the Phase III VIKING-3 study. J Infect Dis. 2014;210:354-62.

12. Triumeq® (dolutegravir/abacavir/lamivudine) US prescribing information. Available at:

Source: ViiV Healthcare
Related stocks: LSE:GSK NYSE:GSK
Related Links:

Written by asiafreshnews

July 19, 2016 at 5:24 pm

Posted in Uncategorized

Yisheng Biopharma and the United States Army Medical Research Institute of Infectious Diseases Announce Positive Animal Results of Vaccine Against Ebola Virus

leave a comment »

BEIJING and FORT DETRICK, Md. /PRNewswire/ — Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of biological vaccines and pharmaceutical products, and the United States Army Medical Research Institute of Infectious Diseases (“USAMRIID”) today announced preliminary positive animal results of a virus-like particle (VLP)-based vaccine in combination with PIKA adjuvant, a Toll-Like Receptor 3 (TLR3) agonist. This study was conducted by the scientists at USAMRIID under the cooperative partnership between the two institutions. The Ebola VLP vaccine was developed by USAMRIID and PIKA is a proprietary product from Yisheng Biopharma.

In this study, the scientists at USAMRIID evaluated the immunogenicity and protective efficacy of their VLP vaccine candidate in a murine model with or without PIKA adjuvant against Ebola virus infection in a laboratory setting. Under the virus challenge study, the group of animals vaccinated without PIKA adjuvant demonstrated 40 percent protection measured by the survival rate; the groups of animals vaccinated with PIKA adjuvant showed 100 percent protection at both high and low dose levels of the PIKA adjuvant. The superior survival rate with PIKA adjuvant was consistent with production of significantly higher antigen-specific antibody titers in comparison to vaccination with VLP alone.

“This is the first time we have evaluated the performance of PIKA adjuvant in combination with our VLP vaccine candidate against Ebola virus infection,” commented Dr. Sina Bavari, Science Director at USAMRIID. “This study provides a solid foundation for us to conduct further studies in exploring safer and more effective vaccine products against Ebola virus infection, which remains a significant unmet medical need,”

“We are very excited to see the first efficacy evidence of our PIKA adjuvant from USAMRIID scientists in Ebola vaccine development. This opens an exciting new arena in identifying clinical candidate Ebola vaccines. We look forward to seeing more data from USAMRIID,” stated Mr. Yi Zhang, Chairman and CEO of Yisheng Biopharma.

According to Mr. Zhang, PIKA adjuvant has demonstrated good safety and robust efficacy in completed and ongoing human trials of PIKA-adjuvanted rabies vaccine. PIKA adjuvant has also exhibited great potential in preclinical studies in vaccines against HIV, Hepatitis-B, influenza, tuberculosis, and other viruses, and the company’s phase 2 PIKA rabies vaccine trial is expected to be completed by the third quarter of this year.

Added Mr. Zhang, “PIKA technology was designated as a ‘National Key Medicine Innovation’ in 2013 and funded by the National Ministry of Science and Technology of China. We are grateful to our research collaborators worldwide for their continuous support in the development of PIKA-adjuvanted vaccines over the years, including The Pasteur Institute, the US NIH, China CDC, China National Institutes For Food and Drug Control, DSO National Laboratories Singapore, Chinese Academy of Sciences, Australia QIMR, Sun Yat-Sen University of China, Aeras Pharmaceutical of the US, and the Academy of Military Sciences of China.”

About Ebola Virus

Ebola hemorrhagic fever (Ebola HF) is a severe, often-fatal disease in humans and nonhuman primates (monkeys, gorillas and chimpanzees) that has appeared sporadically since its initial recognition in 1976. The incubation period for Ebola HF ranges from two to 21 days. The onset of illness is abrupt and is characterized by fever, headache, joint and muscle aches, sore throat, and weakness, followed by diarrhea, vomiting and stomach pain. The current outbreak in West Africa, (first cases notified in March 2014), is the largest and most complex Ebola outbreak since the Ebola virus was first discovered in 1976. There have been more cases and deaths in this outbreak than all others combined. It has also spread between countries, starting in Guinea then spreading across land borders to Sierra Leone and Liberia, by air to Nigeria and USA, and by land to Senegal and Mali.

About PIKA Adjuvant Technology

PIKA adjuvant technology is a proprietary technology developed in-house at Yisheng Biopharma. The adjuvant acts as a toll-like receptor-3 (TLR-3) ligand to the activation of the innate immune cells, such as dendritic cells, macrophages and NK cells. PIKA adjuvant is formulated as a component of PIKA-adjuvant based vaccine.


The mission of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) is to provide leading edge medical capabilities to deter and defend against current and emerging biological threat agents. Research conducted at USAMRIID leads to medical solutions — vaccines, drugs, diagnostics, and information — that benefit both military personnel and civilians. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency’s Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]

About Yisheng Biopharma Co., Ltd.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company headquartered in Beijing, China, focusing on the research, development, manufacturing and sales and marketing of vaccine products, with approximately 1000 employees in China, the USA and Singapore.

Source: Yisheng Biopharma Co., Ltd.
Related Links:

Written by asiafreshnews

July 19, 2016 at 3:34 pm

Posted in Uncategorized

A2 launches Broker Vote 2.0 – the MiFID II Solution

leave a comment »

NEW YORK /PRNewswire/ — A2 Access, a Dealogic-owned company, is proud to announce the release of its resource consumption tracking and broker vote tools. These new features solidify A2’s position as the industry leader in the sellside content aggregation space.

Investment firms and their sellside partners require simple, effective systems that allow them to record and report on resource consumption compliantly. A2 and Dealogic offer this fully integrated and seamless connection.

A2 Tracking maintains a detailed repository of all relevant services provided to investors by sellside partners.
A2 Broker Vote allows for resource consumption-based voting to help clarify the appropriate allocation of budget and commission dollars for the period.
These are customizable, scalable solutions that work for institutions of any size or strategy. “The progress of A2 in client growth and product releases continues to impress us,” Tom Fleming, CEO of Dealogic, said. “It is no wonder they have more than 300 clients and are the dominant player in the space.”

Baker Burleson, Founder & Portfolio Manager at Banbury Partners, noted, “A2 is a must-have product for anyone in investment management,” while Mark Allan, Partner & Head Trader at Scopia Capital, added, “A2 efficiently aggregates our sellside touchpoints in a logical manner. It has improved our ability to analyze consumption data.”

More than 80,000 of the 250,000 research activities logged in A2 Tracking have been submitted by A2’s sellside partners for 50+ hedge fund clients. These investment firms leverage the dataset as the foundation for a robust broker vote, which provides voters with the context of their resource consumption for the period, creating transparency with sellside partners for the first time.


About A2 Access

A2 Access is the industry leader in sellside content aggregation. Founded in 2012 by two former Tiger Cub analysts and an institutional sales representative, the company was designed by investors for investors. A2 Access was acquired by Dealogic in 2015.

About Dealogic

Dealogic offers integrated content, analytics, and technology via targeted products and services to financial firms worldwide. Whether working in capital markets, sales and trading, banking, or compliance, firms rely on Dealogic’s platform to connect and more effectively identify opportunities, execute deals, and manage risk. With 30 years’ experience and a deep understanding of financial markets, Dealogic is a trusted global partner.

Source: Dealogic
Related Links:


Written by asiafreshnews

July 19, 2016 at 3:29 pm

Posted in Uncategorized

Oberoi Hotels & Resorts Voted World’s Best Hotel Brand for the Second Consecutive Year by Travel + Leisure, USA, World’s Best Awards, Readers’ Survey 2016

leave a comment »

NEW YORK /PRNewswire/ — Oberoi Hotels & Resorts has been voted World’s Best Hotel Brand by Travel + Leisure, World’s Best Awards, 2016 for the second consecutive year.

(Photo: )
(Photo: )
(Photo: )

These rankings are the result of a Readers’ Poll conducted by the magazine. Travel + Leisure’s World’s Best Awards are amongst the most prestigious in the travel industry as it is the readers who define excellence in hospitality and travel. Readers rate their experiences and evaluate hotels across the world on the following parameters – rooms and facilities, location, service, restaurants, food and value.

Mr. P.R.S. Oberoi, Executive Chairman, The Oberoi Group said, “I am very proud that Oberoi Hotels & Resorts have been voted the World’s Best Hotel Brand for the second consecutive year. The awards are an affirmation of The Oberoi Group’s unwavering commitment towards offering guests world-class facilities and unparalleled service. I dedicate the award to our people who are our biggest asset and who have worked passionately to ensure our guests receive warm, personalised and caring service.”

Mr. Nathan Lump, Editor at Travel + Leisure said, “It’s a pretty tough thing to be named the best hotel brand for the second consecutive year, but Oberoi Hotels & Resorts have made it to the top spot once again. Thanks not only to the properties of exceptional quality in picture-perfect locations, but also due to service standard that Travel + Leisure readers say go above and beyond.”

Further notes to the Editor:

About Oberoi Hotels & Resorts

Oberoi Hotels & Resorts are synonymous the world over for providing the right blend of service, luxury and quiet efficiency. Internationally acclaimed for all-round excellence and unparalleled levels of service, Oberoi Hotels & Resorts have received innumerable awards and accolades.

A distinctive feature of the Group’s hotels is their highly motivated and well trained staff who provides exceptionally attentive, personalised and warm service. The Group’s luxury hotels have established a reputation for redefining the paradigm of luxury and excellence in service amongst hotels around the world.

For further information, please contact:
Silki Sehgal
Director – Corporate Communications
The Oberoi Group
Telephone: +91-11-2389 0505

Source: Oberoi Hotels & Resorts
Related Links:

Written by asiafreshnews

July 19, 2016 at 3:20 pm

Posted in Uncategorized

Thailand Raises e-Payment Standards to Global Level

leave a comment »

BANGKOK /PRNewswire/ — Electronic Payment or e-Payment may be relatively new for a lot of people but it is fast gaining in popularity due to its convenience and security. The Thai government is jumping on the bandwagon with the launch of its National e-Payment Masterplan to raise the standard of living of the Thai population.

Ascend Group Chief Executive Officer Punnamas Vichitkulwongsa, as chairman of the Thailand e-Payment Association (TEPA)
Ascend Group Chief Executive Officer Punnamas Vichitkulwongsa, as chairman of the Thailand e-Payment Association (TEPA)
Ascend Group Chief Executive Officer Punnamas Vichitkulwongsa, as chairman of the Thailand e-Payment Association (TEPA), said Thailand is moving into the digital payment era. Digital cash has become the norm in developed countries as can be seen in Sweden where only 4.4% of the population uses cash, Canada at 19.5%, the United States at 29.0%, and even Singapore at 30.5%. On the other hand, developing countries still predominantly use cash with the Philippines at 98.1%, Indonesia at 99.9%, India at 99.78%, and Thailand at 98.5%.

The high usage of cash results in a huge management cost and obstacles in access to cash. Carrying an excessive amount of cash to make payments is a security concern and cash is conducive to corruption as its usage can evade taxation. Moreover, cash transactions require documentation thus limiting efficiency in financial management.

As a result, various sectors have gotten together to push forth the National e-Payment Masterplan which involves 5 key factors:

PromptPay allows the population to conduct money transfer using just the 13-digit identification card number. Registration will start in the third quarter of 2016 and will cover telephone numbers in the future.
Replace cash usage with cards and e-Payment by supplying shops nationwide with the Electronic Data Capture (EDC) system by the third quarter of this year.
Once e-Payment becomes more prevalent, tax audit will become more efficient and the need for documents will lessen so work can be streamlined. This should be introduced in the fourth quarter.
The state e-Payment system will be used to pay out welfare through the PromptPay campaign.
Education and support for electronic transactions are important parts in helping Thais know, understand, and use e-Payment efficiently.
By the second half of 2016, money transfers will be possible via the PromptPay scheme. Cross-provincial money transfers, which used to be carried out at commercial banks and waste time and money, have been replaced by Internet Banking but that still faced access restraints. Now, PromptPay will simplify the process and keep the transaction fee very low for consumers and commercial banks.

These are the major changes to Thailand’s financial system but what is also required is an update of the rules and regulations governing the sector, development of the various infrastructure and support systems, and a guarantee of the safety of the technology to be used.

e-Payment is a national agenda that requires cooperation from all sides. It all starts with the registration for PromptPay in July. This will set the path to reset Thailand and generate positive changes to bring the country into the digital era.

Contact information:

Saengduan Sidaeng
Ascend Group Co.,Ltd.
Tel. +668-5805-8550

Photo –

Source: Ascend Group Co.,Ltd.

Written by asiafreshnews

July 19, 2016 at 3:18 pm

Posted in Uncategorized

MEDIA ALERT: Synopsys to Showcase Software Integrity Platform at RSA Conference 2016 Asia Pacific and Japan

leave a comment »

SINGAPORE /PRNewswire/ — Synopsys, Inc. (Nasdaq: SNPS) today announced it will showcase its Software Integrity Platform, a comprehensive suite of software security testing solutions, at RSA Conference 2016 Asia Pacific and Japan. Through a combination of best-in-class automated testing tools, Synopsys’ Software Integrity Platform empowers organizations to reduce risk, cost and time to market by rapidly detecting and fixing critical security vulnerabilities throughout the software development lifecycle and supply chain.

Logo –


Visit Synopsys and its partner M.Tech at booth D2 at the Marina Bay Sands in Singapore from Wednesday, July 20 through Friday, July 22. Learn more about the Software Integrity Platform, including the recently released Coverity® 8.5 static application security testing solution now offered in simplified Chinese.

Synopsys’ Software Integrity Platform is used to facilitate “software signoff,” an integrated development and testing methodology that aims to ensure software quality and security. Pioneered by Synopsys to emulate the signoff concept used in integrated circuit (IC) design, software signoff involves a series of automated testing cycles at critical points throughout the software development lifecycle and software supply chain.

Synopsys security experts will be hosting the following presentations at booth D2 during the course of the conference:

Wednesday, July 20 from 1:10 p.m. -1:25 p.m.

Managing Vulnerabilities in Third-Party Software Components
Heartbleed, ShellShock, Poodle… Vulnerabilities in third-party software components have captured numerous headlines in recent past years. Learn how organizations can gain visibility and manage risk across their software supply chain. During this presentation, we will drill down to the binaries and explore how organizations can mitigate these open- source and third-party vulnerabilities with software composition analysis.

Thursday, July 21, 10:50 a.m. -11:05 a.m.

Augmenting Penetration Testing with IAST
One of the critiques of pen-testing is that it requires extensive expertise and manual work and only provides a fleeting glimpse of an organization’s security posture at a given point in time. Interactive application security testing, or IAST, tools can help organizations to gain continuous visibility and combat threats as they emerge, leveraging automation and advanced runtime analysis technology. During this presentation, we will go through the benefits of IAST testing, and also the value it can bring to make pen-testing more efficient and less time consuming.

Friday, July 22, 12:50 p.m. – 1:05 p.m.

Solving the Common Threat Intelligence Challenges
Harmonization, augmentation, reliability, consistency and timeliness are common challenges that plague organizations implementing a threat intelligence tool. In this presentation, learn how these challenges can be addressed and how a threat intelligence platform can be utilized to harness the power of multiple threat intelligence feeds.

About Synopsys

Synopsys, Inc. (Nasdaq:SNPS) is the Silicon to Software™ partner for innovative companies developing the electronic products and software applications we rely on every day. As the world’s 15th largest software company, Synopsys has a long history of being a global leader in electronic design automation (EDA) and semiconductor IP and is also growing its leadership in software quality and security solutions. Whether you’re a system-on-chip (SoC) designer creating advanced semiconductors, or a software developer writing applications that require the highest quality and security, Synopsys has the solutions needed to deliver innovative, high-quality, secure products. Learn more at

Editorial Contacts:
Mark Van Elderen (Software Integrity Group)
Synopsys, Inc.

Sheryl Gulizia (Corporate)
Synopsys, Inc.

Source: Synopsys, Inc.
Related stocks: NASDAQ-NMS:SNPS
Related Links:

Written by asiafreshnews

July 19, 2016 at 2:33 pm

Posted in Uncategorized

The Dyson Supersonic to Launch in Singapore on 5th August 2016 — First in Southeast Asia

leave a comment »

SINGAPORE /PRNewswire/ — Following the momentous launch in Japan which saw Dyson’s foray from the business of clean into the business of beauty, the Dyson Supersonic hair dryer is due to arrive Singapore. It is slated to hit store shelves on 5th August 2016 for the retail price of S$599, and will be available at major departmental stores and electrical multiples.

The Dyson Supersonic is set to launch in Singapore on 5th August 2016.
The Dyson Supersonic is set to launch in Singapore on 5th August 2016.

To commemorate the launch, Tangs will be doing an exclusive online pre-order at their website ( from 20th July onwards. Customers who pre-order the hair dryer may opt to pick up their machines at Tangs or have them delivered to their homes from 5th August onwards.

As part of the official launch, Dyson will conduct a hair academy with beauty blogger Drea Chong on the evening of 5th August from 7pm – 9pm. Limited spots are available and are on a first-come-first served basis. Parties interested may RSVP at the following link:

Those keen to get up close and personal or have a hands-on with the new technology may visit selected stores including but not limited to Tangs Orchard, Tangs VivoCity, Best Denki VivoCity, and Robinsons JEM from early August.

For information, please contact:

Malvin Chua
PR Executive
Dyson Singapore
DID: +65 6643 2985
M: +65 9230 0443

Sarah Arts
PR Manager, Southeast Asia
Dyson Singapore
DID: +65 6643 2984
M: +65 9138 9166

Photo –
Logo –

Source: Dyson Singapore

Written by asiafreshnews

July 19, 2016 at 2:27 pm

Posted in Uncategorized